Trends in discovery of new drugs for tuberculosis therapy

Bedaquiline

(2014) Elias B. Chahine et al.   ANNALS OF PHARMACOTHERAPY

New Approaches to Target the Mycolic Acid Biosynthesis Pathway for the Development of Tuberculosis Therapeutics

(2014) E. North et al.   CURRENT PHARMACEUTICAL DESIGN

Towards a new combination therapy for tuberculosis with next generation benzothiazinones

(2014) V. Makarov et al.   EMBO Molecular Medicine

An update on the use of rifapentine for tuberculosis therapy

(2014) John Gar Yan Chan et al.   Expert Opinion on Drug Delivery

A review of tuberculosis: Focus on bedaquiline

(2013) B. Chan et al.   AMERICAN JOURNAL OF HEALTH-SYSTEM PHARMACY

The DprE1 enzyme, one of the most vulnerable targets of Mycobacterium tuberculosis

(2013) Giovanna Riccardi et al.   APPLIED MICROBIOLOGY AND BIOTECHNOLOGY

Clinical Benefit of Delamanid (OPC-67683) in the Treatment of Multidrug-Resistant Tuberculosis Patients in China

(2013) Qing Zhang et al.   CELL BIOCHEMISTRY AND BIOPHYSICS

Tuberculosis Clinical Trial Update and the Current Anti-Tuberculosis Drug Portfolio

(2013) Juan Palomino et al.   CURRENT MEDICINAL CHEMISTRY

Treatment of pulmonary tuberculosis

(2013) Andrew Nunn et al.   CURRENT OPINION IN PULMONARY MEDICINE

Vaccine Development for Tuberculosis: Current Progress

(2013) Ian M. Orme   DRUGS

Synthesis of 3-heteryl substituted pyrrolidine-2,5-diones via catalytic Michael reaction and evaluation of their inhibitory activity against InhA and Mycobacterium tuberculosis

(2013) Tetiana Matviiuk et al.   EUROPEAN JOURNAL OF MEDICINAL CHEMISTRY

In vitrosusceptibility testing and totally drug-resistant tuberculosis

(2013) Giovanni Sotgiu et al.   EUROPEAN RESPIRATORY JOURNAL

TheMycobacterium tuberculosisSecreted Protein Rv0203 Transfers Heme to Membrane Proteins MmpL3 and MmpL11

(2013) Cedric P. Owens et al.   JOURNAL OF BIOLOGICAL CHEMISTRY

Multi-drug-resistant tuberculosis in HIV positive patients in Eastern Europe

(2013) Frank A. Post et al.   JOURNAL OF INFECTION

Azaindoles: Noncovalent DprE1 Inhibitors from Scaffold Morphing Efforts, Kill Mycobacterium tuberculosis and Are Efficacious in Vivo

(2013) Pravin S. Shirude et al.   JOURNAL OF MEDICINAL CHEMISTRY

Epidemiology: A mortal foe

(2013) Tom Paulson   NATURE

Advances in the development of new tuberculosis drugs and treatment regimens

(2013) Alimuddin Zumla et al.   NATURE REVIEWS DRUG DISCOVERY

Improved BM212 MmpL3 Inhibitor Analogue Shows Efficacy in Acute Murine Model of Tuberculosis Infection

(2013) Giovanna Poce et al.   PLoS One

Identification of a small molecule with activity against drug-resistant and persistent tuberculosis

(2013) F. Wang et al.   PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA

Indoleamides are active against drug-resistant Mycobacterium tuberculosis

(2013) Shichun Lun et al.   Nature Communications

Resistance in tuberculosis: what do we know and where can we go?

(2013) Keith D. Green et al.   Frontiers in Microbiology

Identification of Novel Inhibitors of M. tuberculosis Growth Using Whole Cell Based High-Throughput Screening

(2012) Sarah A. Stanley et al.   ACS Chemical Biology

In VitroCombination Studies of Benzothiazinone Lead Compound BTZ043 against Mycobacterium tuberculosis

(2012) Benoit Lechartier et al.   ANTIMICROBIAL AGENTS AND CHEMOTHERAPY

SQ109 Targets MmpL3, a Membrane Transporter of Trehalose Monomycolate Involved in Mycolic Acid Donation to the Cell Wall Core of Mycobacterium tuberculosis

(2012) Kapil Tahlan et al.   ANTIMICROBIAL AGENTS AND CHEMOTHERAPY

Totally Drug-Resistant and Extremely Drug-Resistant Tuberculosis: The Same Disease?

(2012) G. B. Migliori et al.   CLINICAL INFECTIOUS DISEASES

Safety and Pharmacokinetics of Escalating Daily Doses of the Antituberculosis Drug Rifapentine in Healthy Volunteers

(2012) K E Dooley et al.   CLINICAL PHARMACOLOGY & THERAPEUTICS

Towards a new tuberculosis drug: pyridomycin - nature's isoniazid

(2012) Ruben C. Hartkoorn et al.   EMBO Molecular Medicine

Discovery and development of SQ109: a new antitubercular drug with a novel mechanism of action

(2012) Katherine A Sacksteder et al.   Future Microbiology

New Drugs for the Treatment of Tuberculosis: Needs, Challenges, Promise, and Prospects for the Future

(2012) Christian Lienhardt et al.   JOURNAL OF INFECTIOUS DISEASES

Inhibition of mycolic acid transport across the Mycobacterium tuberculosis plasma membrane

(2012) Anna E Grzegorzewicz et al.   Nature Chemical Biology

Delamanid for Multidrug-Resistant Pulmonary Tuberculosis

(2012) Maria Tarcela Gler et al.   NEW ENGLAND JOURNAL OF MEDICINE

Structural basis of inhibition of Mycobacterium tuberculosis DprE1 by benzothiazinone inhibitors

(2012) S. M. Batt et al.   PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA

Structural Basis for Benzothiazinone-Mediated Killing of Mycobacterium tuberculosis

(2012) J. Neres et al.   Science Translational Medicine

MmpL3 Is the Cellular Target of the Antitubercular Pyrrole Derivative BM212

(2011) Valentina La Rosa et al.   ANTIMICROBIAL AGENTS AND CHEMOTHERAPY

Totally Drug-Resistant Tuberculosis in India

(2011) Z. F. Udwadia et al.   CLINICAL INFECTIOUS DISEASES

Sequence and Structural Convergence of Broad and Potent HIV Antibodies That Mimic CD4 Binding

(2011) J. F. Scheid et al.   SCIENCE

Clinical Isolates of Mycobacterium tuberculosis in Four European Hospitals Are Uniformly Susceptible to Benzothiazinones

(2010) M. R. Pasca et al.   ANTIMICROBIAL AGENTS AND CHEMOTHERAPY

Early Bactericidal Activity and Pharmacokinetics of PA-824 in Smear-Positive Tuberculosis Patients

(2010) A. H. Diacon et al.   ANTIMICROBIAL AGENTS AND CHEMOTHERAPY

Leads for antitubercular compounds from kinase inhibitor library screens

(2010) Sophie Magnet et al.   TUBERCULOSIS

Triclosan Derivatives: Towards Potent Inhibitors of Drug-Sensitive and Drug-ResistantMycobacterium tuberculosis

(2009) Joel S. Freundlich et al.   ChemMedChem

Emergence of New Forms of Totally Drug-Resistant Tuberculosis Bacilli

(2009) Ali Akbar Velayati et al.   CHEST

Structure, function and inhibition of RND efflux pumps in Gram-negative bacteria: an update

(2009) Jessica MA Blair et al.   CURRENT OPINION IN MICROBIOLOGY

Mycobacterium tuberculosis: drug resistance and future perspectives

(2009) Giovanna Riccardi et al.   Future Microbiology

Benzothiazinones Kill Mycobacterium tuberculosis by Blocking Arabinan Synthesis

(2009) V. Makarov et al.   SCIENCE

High Content Screening Identifies Decaprenyl-Phosphoribose 2′ Epimerase as a Target for Intracellular Antimycobacterial Inhibitors

(2009) Thierry Christophe et al.   PLoS Pathogens

Selectivity of TMC207 towards Mycobacterial ATP Synthase Compared with That towards the Eukaryotic Homologue

(2008) A. C. Haagsma et al.   ANTIMICROBIAL AGENTS AND CHEMOTHERAPY

The RNA Polymerase “Switch Region” Is a Target for Inhibitors

(2008) Jayanta Mukhopadhyay et al.   CELL

Biosynthesis of D-arabinose in mycobacteria - a novel bacterial pathway with implications for antimycobacterial therapy

(2008) Beata A. Wolucka   FEBS Journal

PA-824 Kills Nonreplicating Mycobacterium tuberculosis by Intracellular NO Release

(2008) R. Singh et al.   SCIENCE